ADAR1 Capital Management »

Cortexyme shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Cortexyme (QNCX) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Cortexyme

Tip: Access up to 7 years of quarterly data

All positions including Cortexyme held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cortexyme by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $28k 27k 1.06

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Cortexyme

Tang Capital Management
Vanguard Group
EPIQ Capital Group
Renaissance Technologies
BlackRock
HighTower Advisors
Geode Capital Management
Alphabet
Bank of America Corporation
Bridgeway Capital Management
Susquehanna International
Citadel Advisors
Two Sigma Advisers
Mariner Wealth Advisors
State Street Corporation

View all funds holding Cortexyme